(Q38249061)

English

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

scientific article published on 11 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 September 2017

0 references

1 reference

Europe PubMed Central

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

1 September 2017

type 2 diabetes

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

Bernard Zinman

1 reference

Europe PubMed Central

1 September 2017

author name string

Conrad Eng

1

1 reference

Europe PubMed Central

1 September 2017

Caroline K Kramer

2

1 reference

Europe PubMed Central

1 September 2017

Ravi Retnakaran

4

1 reference

Europe PubMed Central

1 September 2017

language of work or name

0 references

publication date

11 September 2014

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

1 September 2017

384

1 reference

Europe PubMed Central

1 September 2017

9961

1 reference

Europe PubMed Central

1 September 2017

2228-2234

1 reference

Europe PubMed Central

1 September 2017

The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Type 2 diabetes across generations: from pathophysiology to prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacology, physiology, and mechanisms of incretin hormone action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961335-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61335-0

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38249061&oldid=2113930746"